Business Wire

POLYMATERIA

25.2.2021 11:54:08 CET | Business Wire | Press release

Share
A Step Forward for the Circular Economy: Polymateria Open-sources Recyclability Data to Show First Plastic Material to Be Both Recyclable and Biodegradable

Polymateria, who in 2020 became the first company to evidence full biodegradation of plastic in the open environment, has today open-sourced data showing that its Biotransformation technology is recyclable as well as biodegradable.

Heralding a step forward in the shift to a more circular economy, polyethylene filmcontaining Polymateria’s Biotransformation technology has been shown to meet accepted industry protocol for recyclability through independent testing.

Polymateria’s technology demonstrates that the vision of a truly circular economy is possible. An economy where materials are reused or recycled as a matter of priority while allowing any items escaping the system to return to nature without causing any harm. By uniquely time-controlling when biodegradation will start, Polymateria’s technology allows time for recycling to take place before biodegradation is triggered.

Through open-sourcing its data, Polymateria invites other companies to work together to build a truly circular economy. The company is looking forward to working with plastic manufacturers, consumer brands and recyclers to unite the value chain and bring the circular economy vision to life.

Biodegradation of material containing Polymateria’s technology is verified by the British Standard Institution’s (BSI) new PAS 9017 standard for the Biodegradation of polyolefins in an open-air terrestrial environment which was launched in late 2020. The first of its kind, the standard sets a series of stringent pass/fail criteria ensuring full biodegradation with no microplastics or ecotoxicity left behind.

The open-sourced recyclability report from Impact Solutions can be found here .

Nial Dunne, CEO of Polymateria, said:

This is a good day for all those who believe in building a circular economy.

For too long, it has been assumed that biodegradable material cannot also be recycled. Our technology is changing perceptions. Products containing our technology should be recycled as a matter of priority, but any items escaping the system will return to nature at the right time without causing any harm.

As enablers of a circular economy, we invite the industry to join the growing number of partners working with us to bring a circular economy vision to life.

Dr Christopher Wallis, Polymateria SVP of Innovations, said:

I am pleased with the technical recyclability results achieved through the independent testing conducted by Impact Solutions. With these results, we can demonstrate that material containing our technology meets current industry protocol for mechanical recycling of polyolefins.

Dr Michail Kalloudis, Director of Polymer Science at Impact Solutions, said:

Our independent research clearly demonstrates that polyethele film containing Polymateria’s Biotransfromation masterbatch is recyclable within normal mechanical recycling streams. We tested the material stringently against recycling industry protocol.

Dr Simon Hepworth, Director of Enterprise at Imperial College London said:

We are delighted to see the progress being made by Polymateria, first at the White City Incubator and now within the Translation & Innovation Hub (I-HUB), joining a range of deep tech companies and remaining part of Imperial's entrepreneurial ecosystem. As a science-focused business developing technology to address global environmental challenges, we're proud to see them flourish and to continue our role in supporting Polymateria's efforts to build a circular economy.

Technical note:

  • Polyethelene film containing Polymateria’s masterbatch technology was tested by Impact Solutions, UK. The report can be accessed here .
  • Recyclability was tested and proven against the Recyclass “Recyclability Assessment Protocols for PE Films ” version 1.0 published on September 6th 2018.

About Polymateria
Polymateria’s mission is to advance science to help nature deal with the plastic pollution crisis. Born from, and now based at, Imperial College London, we’re the first company in the world to prove scientifically that you can take the most likely sources of fugitive or littered plastic and return them to nature without creating microplastics, harming the natural environment or interfering with recycling streams at scale.

The British Standards Institutions’s new BSI PAS 9017 standard ensures claims of biodegradability in the open environment can be properly verified for the first time according to independent pass/fail criteria. The Standard and Polymateria's technology were recently featured in National Geographic magazine: https://www.nationalgeographic.co.uk/environment-and-conservation/2020/11/new-self-destructing-plastic-has-helped-define-a-new-british

In 2020, Puma became the first international brand to incorporate Polymateria’s technology into its shopping bags: https://www.polymateria.com/wp-content/uploads/2020/07/10663-STim_Polymateria_26072020-A.pdf

Polymateria also has a partnership with international chemical giant Clariant (now Avient) to bring the technology to South-East Asia: https://www.clariant.com/en/Corporate/News/2019/10/Clariant-and-Polymateria-launch-partnership-to-bring-new-Biotransformation-technology-to-market-in-S

Pour Les Femmes, the ethical brand founded by actor/activitist Robin Wright and designer Karen Fowler, is the first apparel brand to introduce Polyamteria’s technology into its packaging: https://pourlesfemmes.com/blogs/blog

The company is proud to be a founding signatory of HRH The Prince of Wales’ Terra Carta (Earth Charter) established under the Sutainanble Markets Initiative.

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release

Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result

Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release

Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said

SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release

In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin

Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release

Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th

SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release

SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye